The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

BIOTECHNOLOGY LAW REPORT, published by MARY ANN LIEBERT, INC, serves as a pivotal platform for professionals and researchers engaged in the intersection of biotechnology and law. This esteemed journal, with ISSN 0730-031X and E-ISSN 1557-8704, provides critical insights into legal issues and regulatory developments surrounding biotechnological innovations. Covering a diverse range of topics from intellectual property rights to environmental law, the journal aims to foster informed dialogue and policy advancements in a rapidly evolving field. Although it currently stands in the Q4 category for both Biotechnology and Management, Monitoring, Policy and Law, the relevance of its content persists alongside its significant contributions from industry experts and academics. Published in the United States, the journal is committed to offering comprehensive coverage of pertinent themes, despite limited open access options. As it converges its publication years towards the future, BIOTECHNOLOGY LAW REPORT remains crucial for those navigating the complexities of biotechnology legislation and its global implications.

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Ph pharmaceuticals is a leading peer-reviewed journal published by MDPI, focused on the dynamic fields of pharmaceutical science, drug discovery, and molecular medicine. Since its inception, the journal has established itself as a vital resource for researchers and practitioners, boasting an impressive impact factor reflected in its Q1 and Q2 quartile rankings across multiple categories, including Pharmaceutical Science and Drug Discovery. As an open access journal since 2009, Pharmaceuticals promotes the dissemination of cutting-edge research and innovative findings globally, facilitating collaboration and knowledge sharing among scientists. With a robust ranking in Scopus, specifically at Rank #56 in Pharmaceutical Science and Rank #65 in Drug Discovery, the journal serves as a critical platform for advancing the field and supporting future developments in therapeutics and pharmaceuticals. Based in Switzerland, Pharmaceuticals continues to inspire a diverse readership of scholars and healthcare professionals who are dedicated to improving health outcomes through innovative research.

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

FOOD AND DRUG LAW JOURNAL is a vital publication dedicated to the intersection of law, public health, and pharmaceutical regulations. Established by the Food Drug Law Institute, this journal serves as an essential resource for legal practitioners, regulatory officials, and researchers focused on the complexities of food and drug legislation. While the journal has not yet achieved open access status, it remains a respected platform for scholarly discourse, reflected in its H-Index and quartile rankings, which place it in Q3 for Law and Q4 in several other relevant fields. Covering diverse topics related to the legal frameworks governing food and drug safety from 1992 to 2018 and continuing its impactful publication from 2021 to 2023, this journal provides critical insights into emerging legal challenges and compliance assurance in the domains of pharmacology and public health. As a publication with a distinct focus on these specialized areas, it aims to advance understanding and influence policy-making, making it a significant asset for professionals and academics alike.

The International Journal of Law and Information Technology, published by Oxford University Press, stands as a leading forum for the exploration of the evolving intersection between law and information technology. With its ISSN 0967-0769 and E-ISSN 1464-3693, this esteemed journal has been at the forefront of academic discourse since its inception in 1993 and is poised to continue influencing the landscape of legal scholarship and information sciences until at least 2024. With a prestigious categorization in the Q2 quartile for both Law and Library and Information Sciences, the journal is prominently ranked in the 76th and 64th percentiles respectively within Scopus rankings. Offering insights on vital themes such as privacy, intellectual property, and technological regulation, the International Journal of Law and Information Technology provides a valuable resource for researchers, practitioners, and students alike, facilitating a deeper understanding of the legal challenges and opportunities presented by technological advancements. While not an open-access publication, the rigorous peer-reviewed articles serve to enrich the global academic community’s knowledge in this critical and dynamic field.

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

ARCHIV DER PHARMAZIE is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to pioneering advances in the fields of Pharmaceutical Science and Drug Discovery. With an impactful history dating back to its inception in 1822, this journal is recognized for its significant contribution to the pharmaceutical sciences, maintaining an impressive Q2 ranking in both the Drug Discovery and Pharmaceutical Science categories as of 2023. The journal’s commitment to excellence is reflected in its Scopus rankings, placing it in the top tiers of relevant fields, ensuring a broad reach and impact among researchers and professionals. Although Open Access options are not available, ARCHIV DER PHARMAZIE continues to be an invaluable resource for scholars seeking to stay abreast of cutting-edge research and developments in pharmacy and related sciences. The journal’s contributions not only serve as crucial benchmarks in research but also enhance the understanding of pharmaceutical innovations, making it essential reading for both seasoned professionals and students alike.